Table 2.
Pathogenetic role of pDCs in cancer.
| Cancer Type | pDC Source | Pathogenetic Mechanism | Reference |
|---|---|---|---|
| Breast cancer | Human cancer tissue | Decreased IFNα production via tumor-derived TNFα, TGFβ | [54] |
| Decreased IFNα production, Tregs expansion | [53] | ||
| Increased Treg proliferation and IL-10 production | [81] | ||
| Ovarian cancer | Human blood—healthy donor | Decreased IFNα production after co-incubation with tumor-derived supernatants, suppressive role of TNFα, TGFβ | [52] |
| Human cancer tissue | Immunosuppression via induction of ICOS+ Tregs producing IL-10, dependent on ICOS-L costimulation | [62] | |
| Human malignant ascites | Induction of neoangiogenesis via TNFα and IL-8 production | [73] | |
| Cervical cancer | Human cord blood | Altered maturation and decreased IFNα production after co-incubation with cervical cancer cell lines, HMGB1 dependent mechanism | [60] |
| Head and neck cancer | Human cancer tissue | Decreased IFNα production upon CpG stimulation, decreased expression of TLR9 | [49] |
| Human blood—healthy donor | Decreased IFNα production after co-incubation with tumor-derived supernatants, suppressive role of IL-10 | [51] | |
| Melanoma | Human cancer tissue | Impaired capacity to secrete IFNα in response to TLR9, induction of Tregs via OX40L and ICOS-L | [64] |
| Lung cancer | Human cancer tissue | Immunosuppression via production of IL-1α | [74] |
| Hepatocellular cancer | Human blood—healthy donor | Regulation of IL-10 production by CD4+ FOXP3- Tregs via ICOS-L upregulation, when exposed to liver tumor lysate | [63] |
| Gastric cancer | Human cancer tissue | Correlation of pDCs and ICOS+ Tregs in peritumoral tissue | [67] |
| Glioma | Mouse model | Decreased IFNα production upon CpG stimulation, decreased expression of TLR9 | [65] |